Stock Analiz

Pacira BioSciences, Inc. (PCRX) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Pacira BioSciences’s revenue went from $276M in fiscal 2016 to $726M in fiscal 2025, growth of about 11.3% a year.

Net income in fiscal 2025 was $7M, a net margin of 1.0%; the best year in this period was 2020 with $146M.

Over the twelve months to September 30, 2026, revenue was $743M and net income $38M.

Free cash flow was $137M in fiscal 2025 and positive in 9 of the 10 years shown.

The diluted share count rose 21% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $276M162017: $287M172018: $337M182019: $421M192020: $430M202021: $542M212022: $667M222023: $675M232024: $701M242025: $726M25$726M
Net income
2016: -$38M162017: -$43M172018: -$471000182019: -$11M192020: $146M202021: $42M212022: $16M222023: $42M232024: -$100M242025: $7M25$7M
Free cash flow
2016: $9M162017: -$1M172018: $34M182019: $60M192020: $39M202021: $80M212022: $115M222023: $139M232024: $179M242025: $137M25$137M
EPS (diluted)
2016: $-1.02162017: $-1.07172018: $-0.01182019: $-0.27192020: $3.33202021: $0.92212022: $0.34222023: $0.89232024: $-2.15242025: $0.1625$0.16

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$743M$726M$701M$675M$667M$542M$430M$421M$337M$287M$276M
Gross profit—$577M$531M$490M$468M$401M$312M$314M$250M$199M$166M
Operating income$36M$19M-$73M$88M$60M$90M$46M$10M$16M-$25M-$32M
Net income$38M$7M-$100M$42M$16M$42M$146M-$11M-$471000-$43M-$38M
EPS (diluted)$0.93$0.16$-2.15$0.89$0.34$0.92$3.33$-0.27$-0.01$-1.07$-1.02
R&D$122M$117M$82M$76M$85M$56M$59M$72M$56M$57M$46M
Revenue growth—+3.6%+3.9%+1.2%+23.1%+26.0%+2.1%+24.8%+17.7%+3.7%+11.0%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$177M$152M$189M$155M$145M$126M$77M$71M$49M$18M$33M
Capital spending-$8M-$15M-$11M-$15M-$30M-$46M-$38M-$10M-$15M-$19M-$25M
Free cash flow$169M$137M$179M$139M$115M$80M$39M$60M$34M-$1M$9M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$98M$148M$25M$0$0——————
Stock-based pay$54M$58M$51M$48M$48M$42M$40M$34M$32M$32M$31M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$238M$485M$279M$289M$656M$522M$292M$383M$311M$173M
Debt—$418M$639M$586M$763M$419M$391M$352M$291M$276M$227M
Equity—$693M$778M$870M$775M$730M$620M$355M$321M$279M$219M
Total assets—$1.3B$1.6B$1.6B$1.7B$2.1B$1.3B$831M$689M$628M$391M
Shares (diluted)41M45M46M52M47M46M44M42M41M40M37M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—79.4%75.7%72.6%70.1%74.1%72.7%74.7%74.2%69.3%60.2%
Operating margin4.8%2.6%-10.5%13.0%9.0%16.6%10.8%2.5%4.7%-8.7%-11.6%
Net margin5.1%1.0%-14.2%6.2%2.4%7.8%33.9%-2.6%-0.1%-14.9%-13.7%
FCF margin22.7%18.8%25.5%20.7%17.3%14.8%9.1%14.3%10.2%-0.5%3.2%
ROIC—1.4%-4.1%4.1%3.1%5.8%3.6%1.2%2.1%-3.5%-5.7%
ROE—1.0%-12.8%4.8%2.1%5.8%23.5%-3.1%-0.1%-15.2%-17.3%

Frequently asked questions

What is Pacira BioSciences’s annual revenue?

$726M in fiscal 2025 and $743M over the twelve months to September 30, 2026.

How much profit does Pacira BioSciences make?

Net income was $7M in fiscal 2025 (net margin 1.0%).

Is Pacira BioSciences’s revenue growing?

Yes: revenue rose 3.6% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.